Bargagli M, Dhayat NA, Anderegg M, et al. - Among participants enrolled in the Bern ADPKD registry (a prospective observational cohort study), researchers investigated if treatment of autosomal dominant polycystic kidney disease (ADPKD) with tolvaptan is related to changes of the urinary lithogenic risk profile. This analysis involved 125 participants (38 with and 87 without Tolvaptan treatment). Lower urine relative supersaturation ratios for calcium oxalate, brushite, and uric acid, as well as higher urine citrate in mmol/mmol creatinine per day and calcium in mmol/mmol creatinine per day excretion, were observed in correlation with tolvaptan treatment, as revealed in multivariable analysis. Overall, experts reported a significantly improved urinary lithogenic risk profile in correlation with tolvaptan treatment in patients with ADPKD.